Eleanor de Groot Biography and Net Worth

EVP of ZIOPHARM Oncology

As EVP, GM Cell Therapy, Eleanor (Ellee) oversees Ziopharm’s cell therapy platform which is being developed in collaboration with MD Anderson Cancer Center in Houston, Texas. Prior to joining the company in 2015, Ellee was Vice President of Technical Operations and Project Planning and Management at Helsinn Therapeutics US, Inc. She has over 20 years of diverse experience in all phases of drug development, particularly in the area of Chemistry, Manufacturing and Controls (CMC). Prior to Helsinn, Ellee held process development roles in Guilford Pharmaceuticals (now Eisai) and Shell Chemical Company. She holds a Ph.D. in chemical engineering from Stanford University, a B.S. in chemical engineering from Massachusetts Institute of Technology (MIT) and an M.B.A. from Rice University.

What is Eleanor de Groot's net worth?: The estimated net worth of Eleanor de Groot is at least $0.00 as of January 4th, 2021. Ms. de Groot owns 206,413 shares of ZIOPHARM Oncology stock worth more than $0 as of November 2nd. This net worth estimate does not reflect any other investments that Ms. de Groot may own. Learn More about Eleanor de Groot's net worth.
How do I contact Eleanor de Groot?: The corporate mailing address for Ms. de Groot and other ZIOPHARM Oncology executives is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. ZIOPHARM Oncology can also be reached via phone at (617) 259-1970 and via email at [email protected]. Learn More on Eleanor de Groot's contact information.
Has Eleanor de Groot been buying or selling shares of ZIOPHARM Oncology?: Eleanor de Groot has not been actively trading shares of ZIOPHARM Oncology during the last ninety days. Most recently, Groot Eleanor De sold 20,132 shares of the business's stock in a transaction on Wednesday, December 22nd. The shares were sold at an average price of $1.27, for a transaction totalling $25,567.64. Learn More on Eleanor de Groot's trading history.
Who are ZIOPHARM Oncology's active insiders?: ZIOPHARM Oncology's insider roster includes Kevin Boyle, Sr. (CEO), Eleanor de Groot (EVP), Heidi Hagen (Director), and Jaime Vieser (Director). Learn More on ZIOPHARM Oncology's active insiders.

Eleanor de Groot Insider Trading History at ZIOPHARM Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/22/2021	Sell	20,132	$1.27	$25,567.64
1/4/2021	Sell	21,620	$2.72	$58,806.40	206,413
1/2/2020	Sell	24,890	$4.55	$113,249.50	174,333

Eleanor de Groot Buying and Selling Activity at ZIOPHARM Oncology

ZIOPHARM Oncology Company Overview

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Today's Range

Now: N/A

50 Day Range

MA: $1.08

$0.82

$1.39

2 Week Range

Now: N/A

Volume

2,127,500 shs

Average Volume

2,008,312 shs

Market Capitalization

$187.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71

Sell NVDA Now?

From Chaikin Analytics | Ad

Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA).